

Treatment of uveal melanoma: where are we now?

Therapeutic Advances in Medical Oncology

10, 175883401875717

DOI: [10.1177/1758834018757175](https://doi.org/10.1177/1758834018757175)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death – A personal view. <i>Progress in Retinal and Eye Research</i> , 2018, 66, 187-199.	7.3	64
2	Overexpression of SLC25A15 is involved in the proliferation of cutaneous melanoma and leads to poor prognosis. <i>Medecine/Sciences</i> , 2018, 34, 74-80.	0.0	4
3	An insight into the molecular genetics of a uveal melanoma patient cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1861-1868.	1.2	4
4	Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 335-345.	2.7	23
5	Management of Patients with Posterior Uveal Melanoma. , 2019, , 185-199.		1
6	Uveal Melanoma: Proton Beam Radiation Therapy. , 2019, , 219-232.		1
7	Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology. <i>Cancers</i> , 2019, 11, 1019.	1.7	28
8	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. <i>Cancers</i> , 2019, 11, 845.	1.7	58
9	Uveal Melanoma: Molecular Pathology. , 2019, , 121-133.		1
10	Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. , 2019, 60, 4187.		30
11	A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. <i>Radiology</i> , 2019, 293, 223-231.	3.6	42
12	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. <i>Cancers</i> , 2019, 11, 1305.	1.7	18
13	The Potential Use of Electrochemotherapy in the Treatment of Uveal Melanoma: In Vitro Results in 3D Tumor Cultures and In Vivo Results in a Chick Embryo Model. <i>Cancers</i> , 2019, 11, 1344.	1.7	24
14	Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma. <i>Molecular Cancer</i> , 2019, 18, 140.	7.9	37
15	Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. <i>Immunogenetics</i> , 2019, 71, 433-436.	1.2	51
17	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019, 11, 817.	1.7	11
18	&lt;p&gt;SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4297-4308.	1.0	16
19	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41

#	ARTICLE	IF	CITATIONS
20	Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. <i>Cancers</i> , 2019, 11, 846.	1.7	66
21	Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. <i>Cancer Imaging</i> , 2019, 19, 31.	1.2	39
22	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019, 19, 415.	1.1	49
23	Understanding Uveal Melanoma Metastasis to the Liver: The Zimmerman Effect and the Zimmerman Hypothesis. <i>Ophthalmology</i> , 2019, 126, 483-487.	2.5	23
24	miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12412-12421.	1.2	52
25	Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. <i>Molecular Cancer</i> , 2019, 18, 159.	7.9	34
26	m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. <i>Molecular Cancer</i> , 2019, 18, 161.	7.9	114
27	Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 1145.	1.3	36
28	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.4	84
29	Differential modulation and prognostic values of immune-escape genes in uveal melanoma. <i>PLoS ONE</i> , 2019, 14, e0210276.	1.1	45
30	Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. <i>Journal of Pathology</i> , 2019, 247, 539-551.	2.1	142
31	Zehn-Jahre multimodale Therapie uvealer Melanome an der Universitätsaugenklinik Innsbruck. <i>Spektrum Der Augenheilkunde</i> , 2020, 34, 18-25.	0.2	0
32	First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. <i>Journal of Nuclear Medicine</i> , 2020, 61, 350-356.	2.8	19
33	Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 458-465.	1.5	2
34	Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients. <i>Ophthalmic Research</i> , 2020, 63, 358-368.	1.0	10
35	An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. <i>Cancers</i> , 2020, 12, 117.	1.7	25
36	Gamma Knife Radiosurgery for Uveal Melanoma: A Retrospective Review of Clinical Complications in a Tertiary Referral Center. <i>Ocular Oncology and Pathology</i> , 2020, 6, 115-122.	0.5	15
38	Mouse models of uveal melanoma: Strengths, weaknesses, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 264-278.	1.5	22

#	ARTICLE	IF	CITATIONS
39	Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival. <i>Life</i> , 2020, 10, 225.	1.1	10
40	Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation. <i>Cancers</i> , 2020, 12, 2923.	1.7	25
41	Unpacking the genetic etiology of uveal melanoma. <i>Expert Review of Ophthalmology</i> , 2020, 15, 211-220.	0.3	2
42	Getting under the skin: The role of CDK4/6 in melanomas. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112531.	2.6	19
43	Quality of life considerations in uveal melanoma patients: a systematic review. <i>Canadian Journal of Ophthalmology</i> , 2020, 55, 413-423.	0.4	4
44	Very late local recurrence of uveal melanoma following successful trans-scleral local resection. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100028.	0.1	0
45	Advances in Clinical Management of Uveal Melanoma. <i>Advances in Ophthalmology and Optometry</i> , 2020, 5, 103-118.	0.3	4
46	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. <i>Oncolmunology</i> , 2020, 9, 1792058.	2.1	30
47	MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5648.	1.8	16
48	BAP1: Not just a BRCA1-associated protein. <i>Cancer Treatment Reviews</i> , 2020, 90, 102091.	3.4	89
49	Chloroquine Sensitizes <i>GNAQ/11</i> -mutated Melanoma to MEK1/2 Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 6374-6386.	3.2	35
50	A Phase II Study of Glematumumab Vedotin for Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2270.	1.7	18
51	Expression of P16INK4a in Uveal Melanoma: New Perspectives. <i>Frontiers in Oncology</i> , 2020, 10, 562074.	1.3	27
52	High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. <i>Cancers</i> , 2020, 12, 2950.	1.7	19
53	Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 756-762.	1.5	7
54	&lt;p&gt;The Economic Value of MR-Imaging for Uveal Melanoma&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 1135-1143.	0.9	10
55	Zebrafish Xenografts for Drug Discovery and Personalized Medicine. <i>Trends in Cancer</i> , 2020, 6, 569-579.	3.8	67
56	<i><sc>GNAQ</sc></i> and <i><sc>GNA</sc> 11</i> mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. <i>British Journal of Dermatology</i> , 2020, 183, 928-939.	1.4	24

#	ARTICLE	IF	CITATIONS
57	Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1538-1543.	0.5	4
58	Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 405.	1.7	28
59	Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. <i>European Journal of Cancer</i> , 2020, 126, 93-103.	1.3	21
60	Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov. <i>Frontiers in Pharmacology</i> , 2019, 10, 1539.	1.6	5
61	Molecular profiling of driver events in metastatic uveal melanoma. <i>Nature Communications</i> , 2020, 11, 1894.	5.8	108
62	Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 1130-1141.	0.7	19
63	Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma. <i>Molecular Cancer Research</i> , 2021, 19, 215-222.	1.5	21
64	Ocular manifestations in phakomatosis pigmentovascularis: Current concepts on pathogenesis, diagnosis, and management. <i>Survey of Ophthalmology</i> , 2021, 66, 482-492.	1.7	7
65	Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111006.	2.5	16
66	Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 34-47.	2.5	11
67	Surgical Considerations of Radiation Plaques and Enucleation. , 2021, , 69-88.		0
68	Estimating Cured Fractions of Uveal Melanoma. <i>JAMA Ophthalmology</i> , 2021, 139, 174.	1.4	18
69	A Novel Ferroptosis-Associated Gene Signature to Predict Prognosis in Patients with Uveal Melanoma. <i>Diagnostics</i> , 2021, 11, 219.	1.3	41
70	Current molecular and clinical insights into uveal melanoma (Review). <i>International Journal of Oncology</i> , 2021, 58, .	1.4	53
71	Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>Journal of Clinical Oncology</i> , 2021, 39, 586-598.	0.8	117
72	Predictive factors of radioinduced complications in 194 eyes undergoing gamma knife radiosurgery for uveal melanoma. <i>Acta Ophthalmologica</i> , 2021, 99, e1458-e1466.	0.6	5
73	Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 928-936.	0.7	11
74	Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.2	5

#	ARTICLE	IF	CITATIONS
75	The Zebrafish Xenograft Models for Investigating Cancer and Cancer Therapeutics. <i>Biology</i> , 2021, 10, 252.	1.3	26
76	Automatic optimization of treatment dosimetry to improve visual outcomes in episcleral plaque brachytherapy. <i>Brachytherapy</i> , 2021, 20, 433-445.	0.2	0
77	Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 251-259.	1.3	1
78	Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2669.	1.8	22
79	How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma. <i>Cancers</i> , 2021, 13, 2043.	1.7	18
80	An Automatic Framework to Create Patient-specific Eye Models From 3D Magnetic Resonance Images for Treatment Selection in Patients With Uveal Melanoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100697.	0.6	7
81	The metabolic adaptation mechanism of metastatic organotropism. <i>Experimental Hematology and Oncology</i> , 2021, 10, 30.	2.0	15
82	Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. <i>Current Protocols</i> , 2021, 1, e110.	1.3	3
83	Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. <i>Radiology and Oncology</i> , 2021, 55, 347-353.	0.6	5
84	Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. <i>Melanoma Research</i> , 2021, 31, 449-455.	0.6	9
85	Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma. <i>Acta Radiologica</i> , 2021, , 028418512110198.	0.5	5
86	Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 196.	3.5	20
87	Uveal melanoma pathobiology: Metastasis to the liver. <i>Seminars in Cancer Biology</i> , 2021, 71, 65-85.	4.3	38
88	Melanoma genomics: a state-of-the-art review of practical clinical applications*. <i>British Journal of Dermatology</i> , 2021, 185, 272-281.	1.4	12
89	A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. <i>Pharmaceuticals</i> , 2021, 14, 749.	1.7	2
90	Case Report. <i>Optometry and Vision Science</i> , 2021, Publish Ahead of Print, 1011-1015.	0.6	0
91	Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review. <i>Cancers</i> , 2021, 13, 4031.	1.7	7
92	Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. <i>Future Oncology</i> , 2021, 17, 4583-4606.	1.1	2

#	ARTICLE	IF	CITATIONS
93	Identification of Prognostic alternative splicing signatures and their clinical significance in uveal melanoma. <i>Experimental Eye Research</i> , 2021, 209, 108666.	1.2	3
94	Metastatic Choroidal Melanoma Presenting as Neovascular Glaucoma. <i>Case Reports in Ophthalmology</i> , 2021, 12, 791-796.	0.3	2
95	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. <i>Biomedicines</i> , 2021, 9, 1311.	1.4	17
96	Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 756001.	1.3	31
98	The Prognostic Values of PARP-1 Expression in Uveal Melanoma. <i>Cells</i> , 2021, 10, 285.	1.8	5
99	Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease. <i>Cell Death and Differentiation</i> , 2021, 28, 1990-2000.	5.0	56
100	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199007.	0.8	25
101	Uveal Melanoma: A Review of Prognostic Factors for Metastases. <i>Current Ophthalmology Reports</i> , 2021, 9, 1-6.	0.5	1
102	Recent Developments in Ocular Oncology. , 2020, , 275-293.		3
103	Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases. <i>Seminars in Interventional Radiology</i> , 2020, 37, 508-517.	0.3	13
104	Clinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experience. <i>Melanoma Research</i> , 2021, 31, 38-48.	0.6	6
105	Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. <i>Journal of Translational Medicine</i> , 2020, 18, 208.	1.8	18
106	Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma. <i>Medical Science Monitor</i> , 2019, 25, 3190-3198.	0.5	10
107	Identification of an immune-related signature for the prognosis of uveal melanoma. <i>International Journal of Ophthalmology</i> , 2020, 13, 458-465.	0.5	12
108	&lt;p&gt;Knockdown of Long Non-Coding RNA LOC100132707 Inhibits the Migration of Uveal Melanoma Cells via Silencing JAK2&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12955-12964.	1.0	6
109	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	1.8	57
110	Is Collaborative Ocular Melanoma Study (COMS) still relevant?. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1385.	0.5	14
111	Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5192.	1.7	9

#	ARTICLE	IF	CITATIONS
113	Epidemiology of Melanoma. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 63.	1.3	158
114	Relative survival rates and presence of complications in uveal melanoma patients after stereotactic radiosurgery. , 2018, 8, .		2
115	Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction. , 2019, 2, 365-380.		3
116	Uveal Melanoma: Mortality. , 2019, , 295-304.		0
118	Đ•ĐĐ•ĐšĐĐĐ•Đ'ĐĐ†Đ;ĐĐĐ- ĐĐĐ"Đ†ĐžĐ†Đ'Đ•Đ•Đ-ĐžĐ'ĐžĐ† (3,8 ĐœĐ"Đ  ) Đ'Đ•ĐžĐšĐ•ĐšĐ;Đ  Đ•Đ-Đ†Đ† ĐœĐĐ•ĐĐĐžĐœĐ" Đ  Đ•Đ		
120	Transcatheter Embolization of Liver Metastases. , 2020, , 287-296.e3.		0
121	An unusual case of metastatic choroidal deposits of renal cell carcinoma presenting with loss of vision. <i>Journal of Postgraduate Medicine</i> , 2020, 66, 220-221.	0.2	0
122	Systemic treatment for metastatic uveal melanoma with anti-PD-1 antibodies. <i>Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overloc</i>	0.0	0
123	Genetic Landscape and Emerging Therapies in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5503.	1.7	17
124	Exosomes: Insights from Retinoblastoma and Other Eye Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7055.	1.8	21
125	Immunoembolization of Liver Metastases from Uveal Melanoma. <i>Digestive Disease Interventions</i> , 2020, 04, 365-368.	0.3	0
126	Antibody-drug conjugates: an evolving approach for melanoma treatment. <i>Melanoma Research</i> , 2021, 31, 1-17.	0.6	4
127	Posttreatment Magnetic Resonance Imaging Surveillance of Head and Neck Cancers. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2022, 30, 109-120.	0.6	3
128	Anticancer effects of mifepristone on human uveal melanoma cells. <i>Cancer Cell International</i> , 2021, 21, 607.	1.8	5
129	Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 27-36.	1.2	4
130	Intravitreal aflibercept combined with transpupillary thermotherapy in the treatment of refractory macular edema due to primary uveal melanoma. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 482.	0.3	0
131	Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1564.	1.8	6
132	Immunological significance of survival-related alternative splicing in uveal melanoma. <i>Aging</i> , 2022, 14, 811-825.	1.4	1



#	ARTICLE	IF	CITATIONS
133	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 997-1004.	1.4	7
134	Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. <i>Cancers</i> , 2022, 14, 782.	1.7	12
135	The m6A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation. <i>Oncogene</i> , 2022, 41, 1281-1297.	2.6	29
137	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1162.	1.7	9
138	Future perspectives of uveal melanoma blood based biomarkers. <i>British Journal of Cancer</i> , 2022, 126, 1511-1528.	2.9	22
139	Integrated Analysis of Genes Associated With Immune Microenvironment and Distant Metastasis in Uveal Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 874839.	1.8	1
140	Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3835.	1.8	7
141	[ <sup>213</sup> Bi] <sup>3+</sup> /[ <sup>111</sup> In]In <sup>3+</sup> -neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma—Structural, Radiochemical, and Biological Evaluation. <i>Bioconjugate Chemistry</i> , 2022, 33, 505-522.	1.8	3
142	New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. <i>Cancer Gene Therapy</i> , 2022, 29, 1819-1826.	2.2	10
143	Local therapy of uveal melanomas. <i>Onkologie (Czech Republic)</i> , 2022, 16, 87-90.	0.0	0
144	Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3660.	1.8	18
145	Identification of Survival-Related Metabolic Genes and a Novel Gene Signature Predicting the Overall Survival for Patients with Uveal Melanoma. <i>Ophthalmic Research</i> , 2022, 65, 516-528.	1.0	6
146	Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?. <i>Cancers</i> , 2021, 13, 6390.	1.7	10
147	New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. <i>Cancers</i> , 2022, 14, 134.	1.7	8
148	Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. <i>Cancers</i> , 2022, 14, 118.	1.7	12
149	Incidence and mortality of uveal melanoma in Australia (1982–2014). <i>British Journal of Ophthalmology</i> , 2023, 107, 406-411.	2.1	13
150	Targeting Oncogenic G1±q/11 in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 6195.	1.7	10
151	Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781162.	1.3	3

#	ARTICLE	IF	CITATIONS
152	RASD2 promotes the development and metastasis of uveal melanoma via enhancing glycolysis. <i>Biochemical and Biophysical Research Communications</i> , 2022, 610, 92-98.	1.0	4
155	JMJD2C mediates the MDM2/p53/IL5RA axis to promote CDDP resistance in uveal melanoma. <i>Cell Death Discovery</i> , 2022, 8, 227.	2.0	5
156	Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 383-394.	1.3	2
157	Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma. <i>Molecular Cancer Research</i> , 2022, 20, 1320-1336.	1.5	2
158	MITF deficiency accelerates GNAQ-driven uveal melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2107006119.	3.3	12
159	The immediate results of choroidal melanoma treatment using stereotactic radiosurgery. <i>Diagnostic Radiology and Radiotherapy</i> , 2022, 13, 95-102.	0.0	0
160	Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting for Hyphema. <i>Diagnostics</i> , 2022, 12, 1312.	1.3	2
161	Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases. <i>Nutrients</i> , 2022, 14, 2353.	1.7	8
162	Cordycepin (3'-Deoxyadenosine) Suppresses Heat Shock Protein 90 Function and Targets Tumor Growth in an Adenosine Deaminase-Dependent Manner. <i>Cancers</i> , 2022, 14, 3122.	1.7	4
163	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. <i>Cancers</i> , 2022, 14, 3094.	1.7	23
164	A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy. <i>Cureus</i> , 2022, , .	0.2	3
165	MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. <i>Immuno-Oncology Technology</i> , 2022, 15, 100089.	0.2	9
166	The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 601-619.	2.1	1
167	Predicted vs Observed Metastasis-Free Survival in Individuals With Uveal Melanoma. <i>JAMA Ophthalmology</i> , 0, , .	1.4	8
168	Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
169	Genome-wide CRISPR knockout screening identified G protein pathway suppressor 2 as a novel tumor suppressor for uveal melanoma metastasis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
170	Characteristics, Treatments, and Survival of Uveal Melanoma: A Comparison between Chinese and American Cohorts. <i>Cancers</i> , 2022, 14, 3960.	1.7	3
171	Consensus statement for metastatic surveillance of uveal melanoma in Scotland. <i>Eye</i> , 0, , .	1.1	1

#	ARTICLE	IF	CITATIONS
172	The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents. <i>Medicinal Research Reviews</i> , 2023, 43, 212-236.	5.0	5
173	Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis. <i>Current Opinion in Ophthalmology</i> , 2022, 33, 585-590.	1.3	6
174	Identification of Immune-Related lncRNAs for Predicting Prognosis and Immune Landscape Characteristics of Uveal Melanoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
175	H <sub>4</sub> picoopa <sup>®</sup> Robust Chelate for <sup>225</sup> Ac/ <sup>111</sup> In Theranostics. <i>Bioconjugate Chemistry</i> , 2022, 33, 1900-1921.	1.8	7
177	Dysregulation of B7 family and its association with tumor microenvironment in uveal melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
178	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 2364-2373.	15.2	45
179	IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 63-74.	1.9	0
180	Liquid Biopsy for Uveal Melanoma. Does It Make Sense?. <i>Oftalmologiya</i> , 2022, 19, 594-602.	0.2	3
181	Automatic Three-Dimensional Magnetic Resonance-based measurements of tumour prominence and basal diameter for treatment planning of uveal melanoma. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 24, 102-110.	1.2	2
182	Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma. , 2022, 63, 14.		2
183	Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. <i>Nature Genetics</i> , 2023, 55, 19-25.	9.4	11
184	Choroidal Melanoma: A Mini Review. <i>Medicines (Basel, Switzerland)</i> , 2023, 10, 11.	0.7	2
185	Investigating the Role of DUSP4 in Uveal Melanoma. <i>Translational Vision Science and Technology</i> , 2022, 11, 13.	1.1	1
186	Genetics and RNA Regulation of Uveal Melanoma. <i>Cancers</i> , 2023, 15, 775.	1.7	8
188	Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities. <i>Journal of Pathology</i> , 2023, 260, 203-221.	2.1	4
189	Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery. <i>Pharmaceuticals</i> , 2023, 16, 598.	1.7	3
190	Novel Therapies for Choroidal Melanoma. , 2022, , 283-290.		0
191	Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1308-1316.	0.6	7

#	ARTICLE	IF	CITATIONS
192	Basis, Diagnosis, and Treatment of Uveal Melanoma. , 0, , .		0
193	Stemming Tumoral Growth: A Matter of Grotesque Organogenesis. Cells, 2023, 12, 872.	1.8	0
194	MODERN METHODS OF LOCAL TREATMENT OF PATIENTS WITH UVEAL MELANOMA WITH LIVER METASTASES. Avicenna Bulletin, 2022, 24, 491-501.	0.0	0
195	Anatomical and Functional Outcomes after Endoresection and Adjuvant Ruthenium Brachytherapy for Uveal Melanoma: A Single-Center Experience. Life, 2023, 13, 902.	1.1	0
196	The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. Current Oncology Reports, 2023, 25, 647-657.	1.8	7
205	Immunotherapy for Ocular Tumors. , 2023, , 1-61.		0
223	Choroidal melanoma. , 2024, , 535-547.		0